Communicating, Educating, and Triage for Patients Receiving Bispecific Antibodies in RRMM.
This on-demand activity is designed to equip advanced practice providers and oncology nurses with practical strategies to communicate, educate, and triage patients receiving bispecific antibodies for relapsed/refractory multiple myeloma (RRMM). Through expert guidance, learners will strengthen their ability to explain bispecific therapies in clear, patient-centered language, facilitate shared decision-making, and recognize early signs of treatment-related toxicities. The program emphasizes real-world tools and streamlined triage approaches that support patient safety, adherence, and timely intervention across community oncology settings.
Credits
ANCC 0.25
AAPA 0.25
Duration
15 min
Accreditor
MER
Supporter
Johnson & Johnson
Available: Jun 27, 2026
Expires: Dec 27, 2026
Target Audience
The proposed CME activities will be designed to meet the professional educational needs of advanced practice providers including nurse practitioners, physician associates and advanced oncology nurses who treat and/or manage patients with multiple myeloma.
Statement of Need
This on-demand activity is designed to equip advanced practice providers and oncology nurses with practical strategies to communicate, educate, and triage patients receiving bispecific antibodies for relapsed/refractory multiple myeloma (RRMM). Through expert guidance, learners will strengthen their ability to explain bispecific therapies in clear, patient-centered language, facilitate shared decision-making, and recognize early signs of treatment-related toxicities. The program emphasizes real-world tools and streamlined triage approaches that support patient safety, adherence, and timely intervention across community oncology settings.
Learning Objectives
- Develop strategies for prevention, early recognition, and management of bispecific antibody-related AEs
- Describe best practices for implementation of bispecific antibodies into treatment workflows in clinical practice
- Evaluate key evidence and recommendations for the use of bispecific antibodies alone and in combinations in the treatment of RRMM.
Faculty
Kevin Brigle, PhD, ANP
SpeakerOncology Nurse Practitioner · VCU Massey Comprehensive Cancer Center · Richmond, VA
Disclosure: Consultant: Janssen, J&J. Speaker: Astra Zeneca, BMS, Karyopharm, Pfizer, Sanofi.
Beth Faiman, PhD, MSN, APN-BC, AOCN®, TCTCN®,FAAN, FAPO
SpeakerHematology/Oncology Nurse Practitioner · Cleveland Clinic Taussig Cancer Institute · Cleveland, OH
Disclosure: Consultant: Sanofi, Janssen, GSK, Pfizer.
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and QDcme. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
ANCC
Medical Education Resources designates this live activity for a maximum of 0.25 ANCC nursing contact hour. Nurses will be awarded contact hours upon successful completion of the activity. Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 0.25 contact hour.
AAPA
Medical Education Resources has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME Credit. Physician Associates should only claim credit commensurate with the extent of their participation.
Funding Statement
This activity is supported by an educational grant from Johnson & Johnson.
Conflict of Interest Policy
MER ensures balance, independence, objectivity, and scientific rigor in all educational activities. Relevant financial relationships are identified and mitigated by MER.
QDcme Education
Communicating, Educating, and Triage for Patients Receiving Bispecific Antibodies in RRMM.
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and QDcme. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
ANCC
Medical Education Resources designates this live activity for a maximum of 0.25 ANCC nursing contact hour. Nurses will be awarded contact hours upon successful completion of the activity. Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 0.25 contact hour.
AAPA
Medical Education Resources has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME Credit. Physician Associates should only claim credit commensurate with the extent of their participation.
What to expect
- Self-paced online learning — complete on your schedule
- Post-test required for credit and certificate
- Certificate emailed on successful completion
- Estimated time: 15 min
Save your progress
Create a free account to track credits, download certificates, and access your program history.
Create Account / Login